Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Feb 24, 2020 | clinicaltrials |
| NCT03146039 | Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB(NICER) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 5, 2020 |
| clinicaltrials |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | withdrawn | — | 0 | University of SouthamptonOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | withdrawn | Phase 3 | 0 | BayerINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01766622 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | withdrawn | Phase 2 | 0 | National Institutes of Health Clinical Center (CC)NIH | 0 | Dec 4, 2019 | clinicaltrials |
| NCT03795272 | Rucaparib Maintenance Therapy in Advanced Cervical Cancer(MaRuC) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer(TopoTxt) | withdrawn | — | 0 | Carilion ClinicOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00257829 | Improving Tumor Oxygenation in Cervical Cancer | withdrawn | Phase 2 | 0 | University of California, IrvineOTHER | 0 | Dec 3, 2018 | clinicaltrials |
| NCT02530606 | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT02470819 | Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer | withdrawn | N/A | 0 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00003821 | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00005645 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02836028 | A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Sep 18, 2018 | clinicaltrials |
| NCT01328067 | Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids | withdrawn | N/A | 0 | InSightecINDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02878980 | An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02872519 | PET Imaging of Ovarian Carcinoma With 18F-FSPG | withdrawn | Early Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00428194 | Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer | withdrawn | Phase 1 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00562185 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT03032614 | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT00600210 | Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer | withdrawn | Phase 2 | 0 | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00900081 | Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT00003865 | Toremifene in Treating Patients With Ovarian Cancer | withdrawn | Phase 2 | 0 | George Washington UniversityOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00603460 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02704650 | Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids | withdrawn | N/A | 0 | Shaare Zedek Medical CenterOTHER | 0 | Apr 27, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT02067637 | Delayed Effects of Treatment in Cancer Survivors (DETECS)(DETECS) | withdrawn | — | 0 | University of Colorado, DenverOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01971060 | a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.(VLocmyo) | withdrawn | N/A | 0 | The Advanced Gynecologic Surgery InstituteOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00452920 | Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00842582 | Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer | withdrawn | Phase 1 | 0 | Loyola UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02667925 | Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin(ISOTOVE) | withdrawn | N/A | 0 | Centre Jean PerrinOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT02042495 | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | withdrawn | Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02348398 | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 16, 2016 | clinicaltrials |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01514955 | An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer(IMRT) | withdrawn | Phase 1 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 25, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2020source: clinicaltrials